The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1 and Simvastatin-Induced Myopathy: 2014 Update

• DOI: 10.1038/clpt.2014.125
• Publication Date: 2014-06-11T13:13:46Z
• Authors: L B Ramsey; S G Johnson; K E Caudle; C E Haidar; D Voora; R A Wilke; W D Maxwell; H L McLeod; R M Krauss; D M Roden; Q Feng; R M Cooper-DeHoff; L Gong; T E Klein; M Wadelius; M Niemi
• Keywords: SLCO1B1; Guideline

Simvastatin is among the most commonly used prescription medications for cholesterol reduction. A single coding single-nucleotide polymorphism, rs4149056T>C, in SLCO1B1 increases systemic exposure to simvastatin and risk of muscle toxicity. We summarize evidence from literature supporting this association provide therapeutic recommendations based on genotype. This article an update 2012 Clinical Pharmacogenetics Implementation Consortium guideline simvastatin-induced myopathy.